Optiscan Imaging Limited · ASX:OIL
Optiscan Imaging — Investor Presentation
20 slides from Optiscan Imaging's investor presentation

Slide 1: A Revolution in Medical Imaging
A Revolution in Medical Imaging

Slide 2: Executive Summary
Executive Summary Optiscan is a commercial-stage company that has developed a unique, cutting- edge technology that enables sub-cellular live microscopic imaging. Optiscan is currently focused on driving a step change in cancer diagnostics: • High global incidence of cancer (over 19 million new case

Slide 3: Optiscan: Who We Are
OVERVIEW TECHNOLOGY PRODUCT APPLICATION FUTURE Optiscan: Who We Are Optiscan is the global leader in real-time non-destructive digital microscopic imaging for medical applications. Optiscan has developed biopsy-free, slide-free, non-invasive, live sub-cellular imaging technology. OUR PURPOSE To enab

Slide 4: Optiscan Board: Experienced Leadership
OVERVIEW TECHNOLOGY PRODUCT APPLICATION FUTURE Optiscan Board: Experienced Leadership Dr Camile Farah Robert Cooke Sean Gardiner Karen Borg Ron Song CEO & MD Board Chair Non-Executive Director Non-Executive Director Non-Executive Director • Proven track record • Managing • Medtech leader • Track rec

Slide 5: Improving Cancer Outcomes: A Global Challenge
OVERVIEW TECHNOLOGY PRODUCT APPLICATION FUTURE Improving Cancer Outcomes: A Global Challenge 1 2 3 4 High, growing Cancer treatment Frozen section Traditional cancer rates are a lacks accuracy and procedure is time- Challenge histopathology is not huge burden on results in high consuming, costly ins

Slide 6: Optiscan: A Revolution in Medical Imaging
OVERVIEW TECHNOLOGY PRODUCT APPLICATION FUTURE Optiscan: A Revolution in Medical Imaging Optiscan Has Developed Cutting-Edge Technology… • Real-time, non-invasive, point-of-care microscopic imaging • Opportunity to continuously image and monitor disease • Unlimited sampling across diseased tissue Me

Slide 7: Customer Value Proposition
OVERVIEW TECHNOLOGY PRODUCT APPLICATION FUTURE Customer Value Proposition Patients & Clinicians & Insurers & Advocates Hospital Executives Healthcare Providers High resolution, real-time Non-invasive diagnostic imaging Established CPT reimbursement digital microscopic imaging and better surgical out

Slide 8: Optiscan Advantage: The Leader in Digital Microscopic Imaging
OVERVIEW TECHNOLOGY PRODUCT APPLICATION FUTURE Optiscan Advantage: The Leader in Digital Microscopic Imaging Cutting-edge Technology Practical, Advanced Functionality Unique Miniaturised Confocal User Control of All Key Parameters Endomicroscope • Completely adjustable functionality to • Combination

Slide 9: Technology: Excellent Correlation to Conventional Histopathology
OVERVIEW TECHNOLOGY PRODUCT APPLICATION FUTURE Technology: Excellent Correlation to Conventional Histopathology Cancer vs Normal Correlation with Histopathology Oesophagus Colon Breast Endometrium Mesothelioma Pituitary Adenoma OPTISCAN NORMAL HISTOPATHOLOGY CANCER 9

Slide 10: Technology: Superior to Alternatives
OVERVIEW TECHNOLOGY PRODUCT APPLICATION FUTURE Technology: Superior to Alternatives Process Result • A single optical fibre • Fluorescence intensity projects a pinpoint of variations are mapped, laser light into live creating real-time digital tissue in a scanned microscopic images raster pattern •

Slide 11: Technology: Superior to Alternatives
OVERVIEW TECHNOLOGY PRODUCT APPLICATION FUTURE Technology: Superior to Alternatives Technology Image – Mouse Ilium Comparison Single fibre Whole imaging plane is scanned No blank spots, all critical clinical information displayed No image processing, stitching or mosaicking required Sub-mi

Slide 12: Customer Validation: Positive, Enthusiastic Feedback
OVERVIEW TECHNOLOGY PRODUCT APPLICATION FUTURE Customer Validation: Positive, Enthusiastic Feedback User Testimonials Media Coverage Prof. Mark C. Preul Neurosurgeon, Newsome Chair of Neurosurgery Research, Barrow Neurosurgical Institute, Arizona, USA “This probably is the most exciting technology t

Slide 13: Product History: Multiple Successful Device Launches
OVERVIEW TECHNOLOGY PRODUCT APPLICATION FUTURE Product History: Multiple Successful Device Launches Current Product Range 1995 1999 2006 2007 2018 2018 2023 F-900 Stratum Pentax ISC 1000 FIVE1 ViewnVivo® Zeiss CONVIVO InVivage® Desktop Confocal Skin Imaging Pentax– Optiscan Laboratory Laboratory Lif

Slide 14: Product Suite: Differentiated Clinical & Research Devices
OVERVIEW TECHNOLOGY PRODUCT APPLICATION FUTURE Product Suite: Differentiated Clinical & Research Devices InVivage® Clinical Device ViewnVivo® Research Device FEATURES FEATURES • Push-button handpiece for easy operator use • Miniaturised hand-held probe with 4 mm diameter tip • Advanced software user

Slide 15: Product Partnerships: Successful Commercialisation
OVERVIEW TECHNOLOGY PRODUCT APPLICATION FUTURE Product Partnerships: Successful Commercialisation ISC-1000 CONVIVO Flexible Endomicroscopy Rigid Endomicroscopy System for Gastroenterology System for Neurosurgery • Pentax is a leading Japanese brand developing medical devices and • Zeiss is a leading

Slide 16: Platform Technology: Wide Range of Applications
OVERVIEW TECHNOLOGY PRODUCT APPLICATION FUTURE Platform Technology: Wide Range of Applications Brain ENT Airways Esophagus Pleura Stomach Breast Small bowel Pancreas Liver Cartilage Colon Tendons Ovary Bladder Cervix Prostate Optiscan’s platform technology has broad applications – it can be used whe

Slide 17: Current Clinical Applications: Large, Relevant Target Market
OVERVIEW TECHNOLOGY PRODUCT APPLICATION FUTURE Current Clinical Applications: Large, Relevant Target Market Cancer Cases Healthcare Spend 50k 100 Optiscan 604k 80 Focus Areas 39% 1.5m 60 3.6m 40 Others 61% 20 0 Breast Gastrointestinal (GI) Cervical Head / Neck Total US Cancer Cases Optiscan Focus Ar

Slide 18: Current Clinical Applications: Game Changing Technology
OVERVIEW TECHNOLOGY PRODUCT APPLICATION FUTURE Current Clinical Applications: Game Changing Technology CHALLENGE Breast Gastrointestinal Oral, Head and Neck Of women with early breast High recurrence rates for GI cancer High recurrence rates, with over 50% of cancer, 7-11% experience local (China: 6

Slide 19: Roadmap of Future Applications: Huge Potential
OVERVIEW TECHNOLOGY PRODUCT APPLICATION FUTURE Roadmap of Future Applications: Huge Potential Revolutionising Healthcare Telepathology & Remote Integration with Robotics Biopsy Channel Image-guided AI Based Identification Diagnostics Systems Compatible Devices Molecular Surgery & Diagnostics • Real-

Slide 20: Optiscan
Optiscan”
Source: company website
More decks from Optiscan Imaging Limited
Bell Potter Healthcare Conference (November 2026)11 slides · Nov 17, 2026
Investor Presentation (December 2025)37 slides · Dec 4, 2025
Shareholder Meeting (November 2025)40 slides · Nov 14, 2025
ASX SMIDcaps Conference, Sydney 202522 slides · Sep 24, 2025
Corporate Update (April 2025)26 slides · Apr 10, 2025
TSN ASX Gems Conference (March 2025)16 slides · Mar 28, 2025